NeurAxis Upgrade Behind the Scenes
Removal of the "going concern" qualification is likely
In our last article on NeurAxis (NRXS), we walked through what CEO Brian Carrico disclosed on the Q4 2025 earnings call: prior authorization requests in Q1 2026 are running at approximately 10 times the level in Q1 2025. We expect record revenue. That is the primary catalyst, but a secondary milestone is quietly forming in the background, has received almost no attention, and could materially expand who can own this stock. It is the removal of the “going concern” qualification. This article is about what that means, why Q1 makes it probable, and what happens to NeurAxis’s institutional profile when the qualification is removed.
What the CFO said
On the Q4 2025 earnings call, CFO Timothy Henrichs made a statement that was easy to miss amid the noise around the PA volume disclosure. He said the company raised an incremental $2.6 million subsequent to year-end through its at-the-market equity facility and warrant exercises, bringing current cash above $6 million. He then explained that given the current Q1 burn rate, the balance sheet “provides us with sufficient capital to execute on our growth plans with no near-term need for additional financing at this time.”
That is management signaling, in plain language on a recorded earnings call, that they intend to make the formal mitigating case against the going concern in the next quarterly filing. It is the public preview of the argument the company will present to its auditors.
To understand why this matters, let’s examine the going concern concept.
Mechanics
Under ASC 205-40 of the US generally accepted accounting practices (GAAP), management must assess at each reporting period whether conditions raise substantial doubt about the company’s ability to continue as a going concern for 12 months from the date the financial statements are issued. The NRXS Q1 2026 10-Q, which will be filed around mid-May 2026, requires a look-forward to approximately May 2027.
NeurAxis has carried a going concern qualification in every filing since its IPO. The trigger has always been the same: meaningful operating losses, cash burn exceeding revenue, and a balance sheet that does not cover 12 months of operations without additional capital. The auditors are not wrong to flag it. It is an accurate description of the financial condition of a pre-commercialization medical device company.
But ASC 205-40 also provides a path to removal if management can demonstrate that its mitigation plans, which include projected revenue, existing cash, and available capital facilities, substantially eliminate doubt over the 12-month window. The keyword is “substantially.” The bar is not a certainty but a credible, well-supported argument.
Overcoming the burn rate
Current cash is above $6 million, roughly equal to the annual burn rate. The 12-month look-forward requires covering approximately 5 quarters from mid-May 2026
On cash alone, the company is one quarter short before revenue is factored in. At $2 million in Q1 revenue, which is about 15% of the incremental PA volume, the gross profit of approximately $1.50 million matches the quarterly operating expense levels and meets the 12-month test, removing the going concern. Management has the option of utilizing the remaining ATM and warrant conversion, and the burn rate may change from our estimate, but the framework is there for overcoming the burn rate.
What it means for hospitals
When a hospital system evaluates whether to commit to integrating IB-Stim into its workflow, it is not making a one-time purchase decision. It is making an infrastructure decision. Training staff takes time. Building the prior authorization process takes time. Setting up the billing pathway takes time. These are real operational investments by the hospital.
No hospital administrator making that investment wants to discover six months later that their device vendor has folded or is in financial distress. The going concern qualification, while routine language for early-stage med-tech companies, is visible in public filings. Procurement teams doing diligence on vendors find it. Risk committees review it. In some hospital systems, it is a formal disqualifying factor in vendor approval processes.
The commercial team will not be able to quantify how many hospital conversations were slowed by this concern. NeurAxis has mitigated some customer concerns, but removing it eliminates a friction point in the sales cycle at a time when NeurAxis is trying to accelerate adoption.
Analyst coverage
NeurAxis currently has two sell-side analysts: Karen Sterling, PhD, CFA, at Kingswood US, and the team at Craig-Hallum. Both maintain Buy ratings. Craig-Hallum’s current price target is $13.00. That is the complete analyst coverage universe for a company with a potential $5 billion TAM in the pediatric market and a commercial inflection now underway.
The going concern qualification is a structural barrier to initiating additional coverage. Most sell-side analysts at mid-tier and larger firms operate under internal compliance guidelines that either prohibit or significantly discourage initiating coverage on going concern companies. The logic is straightforward: recommending a stock with existential financial risk exposes the firm to liability if the company fails, regardless of how well-reasoned the investment thesis is.
Going concern removal changes this calculus. Once the qualification is lifted, NeurAxis becomes a commercial-stage medical device company with a Category I CPT code, 100 million covered lives and growing, a VA contract, an FDA-cleared adult indication, and a Q1 2026 revenue print that has the potential to be the most dramatic single-quarter acceleration in the company’s history. That is a story a healthcare analyst at a regional or specialty firm can initiate coverage on without a compliance conversation.
Every incremental analyst who initiates coverage expands the investor awareness funnel. It does not guarantee a price move, but it expands the denominator of investors who know NRXS exists. For a micro-cap trading below $100 million in market capitalization, the initiation of additional coverage is a legitimate re-rating catalyst.
Future dilution
The removal of a going concern does not end dilution, but it ends survival dilution. The company may still add funds through dilutive methods, such as tapping the unused portion of the October 2025 $6.27 million ATM and exercising warrants. We will monitor this process, looking for revenue growth to exceed share count growth. This is the best kind of dilution: it brings in capital at a strike price the warrant holders already committed to, it costs the company nothing to execute, and it strengthens the balance sheet.
NeurAxis’s forward dilution profile:
Approximately $1.2 million in ATM capacity remains.
Approximately 1,230,546 warrants remain outstanding at a $2.38 exercise price. NeurAxis will receive $2.93 million from the conversion of these deep-in-the-money warrants.
Conclusion
The Q1 2026 10-Q filing, expected around mid-May, may be the most consequential financial document NeurAxis has ever published. The going concern removal is not the headline. The revenue print is the headline. But the removal of the going concern is a signal to investors that the headline is not a one-quarter anomaly, but the beginning of a durable commercial trajectory, after several years of building the infrastructure that made this possible.
This article is for informational purposes only and does not constitute investment advice. All figures sourced from the NeurAxis FY2025 Form 10-K, Q4 2025 earnings call transcript, and SEC filings. Always do your own due diligence.